Assembly Biosciences, Inc.
HealthcareNASDAQ:ASMB · NASDAQ Global Select
+$0.43 today
Vol 0.14M · Avg 0.14M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-3.0%
avg -62.2%
ROIC
-5.8%
avg -46.0%
ROA
-2.4%
avg -37.8%
Analysis
ROA is currently the strongest return metric at -2.4% versus its period average of -37.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jason A. Okazaki | Chief Executive Officer, President & Director | $1.25M | — | 50 | $163,354.00 | 1.03% |
William E. Delaney | Chief Scientific Officer | $829,367.00 | — | 54 | $45,642.00 | 0.29% |
Anuj Gaggar | Chief Medical Officer | $820,673.00 | — | 48 | $42,688.00 | 0.27% |
Nicole S. White | Chief Manufacturing Officer | $655,840.00 | — | 46 | $37,486.00 | 0.24% |
Thomas E. Rollins | Executive Officer | $472,550.00 | — | 70 | $67,500.00 | 0.42% |
Amy Figueroa | Investor Relations Consultant | — | — | — | — | — |
Katie Kitrinos | Senior Vice President of Preclinical Research & Development | — | — | — | — | — |
Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management | — | — | — | — | — |
Jennifer A. Troia MHROD SHRM-SCP SPHR | Chief Human Resources Officer | — | — | — | — | — |
Jeanette Bjorkquist | Principal Financial Officer, Executive Director of Accounting & Treasury | — | — | 39 | $11,105.00 | 0.07% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$49.59M
Sells
4
$14,012.35
Net Sentiment
+$49.58M
Net buying
Most Active
GILEAD SCIENCES, INC.
3 transactions
Analysis
Insiders reported 3 buys worth $49.59M and 4 sells worth $14,012.35 over the last 12 months. That adds up to net buying of $49.58M. GILEAD SCIENCES, INC. was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Zura Bio Limited
NASDAQ:ZURA
$240.58M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Who manages ASMB?
Assembly Biosciences, Inc. (ASMB) lists 10 active executives. The top listed executive is Anuj Gaggar, Chief Medical Officer.
Are ASMB insiders buying or selling?
Recent insider activity shows net buying of $91.33M.
Explore More
Continue the stock analysis
Jump to another research area for this company.